- Home
- TEAF vs BDSX Comparison
TEAF vs BDSX Comparison
Compare TEAF & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEAF
- BDSX
- Stock Information
- Founded
- TEAF 2017
- BDSX 2005
- Country
- TEAF United States
- BDSX United States
- Employees
- TEAF N/A
- BDSX N/A
- Industry
- TEAF Trusts Except Educational Religious and Charitable
- BDSX Precision Instruments
- Sector
- TEAF Finance
- BDSX Health Care
- Exchange
- TEAF Nasdaq
- BDSX Nasdaq
- Market Cap
- TEAF 174.8M
- BDSX 189.1M
- IPO Year
- TEAF N/A
- BDSX 2020
- Fundamental
- Price
- TEAF $11.99
- BDSX $1.41
- Analyst Decision
- TEAF
- BDSX Strong Buy
- Analyst Count
- TEAF 0
- BDSX 4
- Target Price
- TEAF N/A
- BDSX $3.08
- AVG Volume (30 Days)
- TEAF 56.1K
- BDSX 648.1K
- Earning Date
- TEAF 01-01-0001
- BDSX 11-01-2024
- Dividend Yield
- TEAF 9.20%
- BDSX N/A
- EPS Growth
- TEAF N/A
- BDSX N/A
- EPS
- TEAF N/A
- BDSX N/A
- Revenue
- TEAF N/A
- BDSX $65,562,000.00
- Revenue This Year
- TEAF N/A
- BDSX $46.97
- Revenue Next Year
- TEAF N/A
- BDSX $30.43
- P/E Ratio
- TEAF N/A
- BDSX N/A
- Revenue Growth
- TEAF N/A
- BDSX 48.92
- 52 Week Low
- TEAF $11.11
- BDSX $1.11
- 52 Week High
- TEAF $13.30
- BDSX $2.21
- Technical
- Relative Strength Index (RSI)
- TEAF 21.36
- BDSX 52.96
- Support Level
- TEAF $12.61
- BDSX $1.24
- Resistance Level
- TEAF $12.68
- BDSX $1.39
- Average True Range (ATR)
- TEAF 0.10
- BDSX 0.09
- MACD
- TEAF -0.05
- BDSX 0.01
- Stochastic Oscillator
- TEAF 4.25
- BDSX 69.81
About TEAF Ecofin Sustainable and Social Impact Term Fund
Tortoise Essential Assets Income Term is a US-based non-diversified, closed-end management investment company. Its investment objective is to provide common shareholders with a high level of total return with an emphasis on current distributions.
About BDSX Biodesix Inc.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.